# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k103373   
B. Purpose for Submission: New Device   
C. Measurand: Cholinesterase   
D. Type of Test: Quantitative absorbance assay   
E. Applicant: Beckman Coulter, Inc.   
F. Proprietary and Established Name SYNCHRON $^ \mathrm { \textregistered }$ Systems Cholinestera   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DIH</td><td rowspan=1 colspan=1>Class I, reserved</td><td rowspan=1 colspan=1>862.3240 -Cholinesterase testsystem</td><td rowspan=1 colspan=1>91 - Toxicology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below

2. Indication(s) for use: System reagent for the quantitative determination of Cholinesterase activity (E.C.

3.1.1.8) in human serum and plasma on Beckman Coulter Synchron $\mathrm { C X @ }$ Pro System(s), Synchron $\mathrm { L X } @$ Pro System(s) and UniCel $^ \mathrm { \textregistered }$ DxC 600/800 System(s).

Measurements obtained by this device are used in the diagnosis and treatment of cholinesterase inhibition disorders (e.g., insecticide poisoning and succinylcholine poisoning).

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Beckman Coulter Synchron $\mathrm { C X @ }$ PRO, Synchron LX $^ \mathrm { \textregistered }$ PRO, or UniCe $^ \mathrm { \textregistered }$ DxC 600/800 System

# I. Device Description:

The device is an in-vitro quantitative assay for the detection of cholinesterase in human serum and plasma. The device consists of two ready to use liquid reagents; a Chromogen Solution (R1), and a Substrate Solution (R2). The reagents and samples are pippetted and analyzed by spectroscopy on the Beckman Coulter analyzers specified above.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Beckman Coulter AU Cholinesterase Assay Kit

2. Predicate 510(k) number(s): k030045

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Indication for use/Intended use</td><td colspan="1" rowspan="1">For the quantitativedetermination ofCholinesterase activity inhuman serum and plasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Two reagents, liquid,ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">1 - 15 kU/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On Board Stability</td><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">FundamentalTechnology</td><td colspan="1" rowspan="1">Chromogenic colorchange</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Anaylyzers</td><td rowspan=1 colspan=1>CX5 PRO, CX9PRO,LX20 PRO, DxC600,DxC800</td><td rowspan=1 colspan=1>AU400/400e/480,AU600/640/640e,AU2700/5400</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum, Li HeparinPlasma, Na HeparinPlasma</td><td rowspan=1 colspan=1>Serum, Li HeparinPlasma, Na HeparinPlasma,EDTA plasma</td></tr><tr><td rowspan=1 colspan=1>Interferences</td><td rowspan=1 colspan=1>Hemoglobin 1000 mg/dLBilirubin 60 mg/dLLipemia 2000 mg/dLAscorbic Acid 30 mg/dL</td><td rowspan=1 colspan=1>Hemoglobin 500 mg/dLBilirubin 40 mg/dLLipemia 1000 mg/dLAscorbic Acid 20 mg/dL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A2: Evaluation of Precision Performance of Quantitative Measurement Methods

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A statistical Approach

CLSI EP07: Interference Testing in Clinical Chemistry

CLSI EP09-A2: Method Comparison and Bias Estimation Using Patient Samples: EP09-A2

CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation

# L. Test Principle:

The Beckman Coulter SYNCHRON Cholinesterase (CHEX) assay is a rate measurement assay based upon enzyme kinetics; a spectrophotometer in the SYNCHRON analyzers measures the change in the absorbance of a chromophore in the reaction. Cholinesterase present in the sample being measured catalyses the hydrolysis of butyrylthiocholine, present in the substrate reagents to butyrate and thiocholine. Thiocholine reduces yellow hexacyanoferrate (III), which is present in the chromogen reagent to colorless hexacyanoferrate (II). Hexacyanoferrate (III) absorbs at $4 1 0 \mathrm { n m }$ , while hexacyanoferrate (II) is colorless and does not absorb at $4 1 0 \mathrm { n m }$ , therefore the decrease in absorbance at $4 1 0 \mathrm { n m }$ is directly proportional to the cholinesterase activity in the sample. A molar extinction coefficient of $9 3 8 . 5  { \mathrm { M } } ^ { - 1 }  { \mathrm { c m } } ^ { - 1 }$ at $4 1 0 \mathrm { n m }$ is used to determine the molar rate of change of hexocyanoferrate (III) to hexocyanoferrate (II), from which the Enzyme activity is calculated by the analyzer.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Within-run and total imprecision studies were designed from CLSI Guideline EP5-A2, “Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline – Second Edition.” The experimental design utilizes duplicate sample analysis, twice daily, over the course of twenty working days. Multi-level control materials as well as pooled human serum samples were used to demonstrate acceptable imprecision within the specifications selected for each sample type.

Results of the within run and total imprecision evaluation for representative members of the SYNCHRON family of Clinical Chemistry analyzers, the UniCel DxC systems, SYNCHRON LX20 PRO system, and SYNCHRON CX PRO systems, are summarized below.

<table><tr><td colspan="5" rowspan="1">Within-run Precision</td></tr><tr><td colspan="1" rowspan="1">Sample*</td><td colspan="1" rowspan="1">Mean(kU/L)</td><td colspan="1" rowspan="1">S.D.(kUL)</td><td colspan="1" rowspan="1">%C.V.</td><td colspan="1" rowspan="1">N</td></tr><tr><td colspan="5" rowspan="1">Within-Run Imprecision - CX5</td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="5" rowspan="1">Within-Run Imprecision - CX9</td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="5" rowspan="1">Within-Run Imprecision - LX20</td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="2" rowspan="1"></td><td colspan="2" rowspan="1">Within-Run Imprecision - DxC 800</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.8</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.4</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="2" rowspan="1"></td><td colspan="2" rowspan="1">Within-Run Imprecision1DxC 600</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="5" rowspan="1">Total Precision</td></tr><tr><td colspan="1" rowspan="1">Sample*</td><td colspan="1" rowspan="1">Mean(kU/L)</td><td colspan="1" rowspan="1">S.D.(kUL)</td><td colspan="1" rowspan="1">%C.V.</td><td colspan="1" rowspan="1">N</td></tr><tr><td colspan="5" rowspan="1">Total Imprecision - CX5</td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="5" rowspan="1">Total -Run Imprecision - CX9</td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1">Total -Run Imprecision - LX20</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Total -Run</td><td colspan="1" rowspan="1">Total -Run Imprecision -1</td><td colspan="1" rowspan="1">-DxC 800</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.8</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.4</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Total -Run</td><td colspan="2" rowspan="1">Total -Run Imprecision  DxC 600</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">LQC1 (control)</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">LQC2 (control)</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPHI (serum pool)</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPLO (serum pool)</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SPMID (serum pool)</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 1 (control)</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 2 (control)</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">SYN 3 (control)</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">80</td></tr></table>

# b. Linearity/assay reportable range:

The linear and reportable range of the SYNCHRON Systems Cholinesterase (CHEX) reagent is $1 { - } 1 5 \mathrm { k U } / \mathrm { L }$ .

The sponsor performed their linearity studies in accordance with CLSI guidelines EP6-A. “Evaluation of the Linearity of Quantitative Measurement Procedures: $A$ Statistical Approach.”. The study protocol utilized serum samples at 7 levels of cholinesterase ranging from approximately 0.6 to $1 7 \mathrm { k U / L }$ tested $( \mathrm { n } { = } 4 )$ on representative members of the SYNCHRON family of Clinical Chemistry analyzers: the UniCel DxC systems, SYNCHRON LX20 PRO system, and SYNCHRON CX PRO systems. The recovered cholinesterase values were plotted against the expected values and an appropriate line fitted by standard linear regression and all of the recovered values were within $6 \%$ of the expected values. These studies demonstrate that the device is linear across its claimed measuring range of $1 { - } 1 5 \mathrm { k U } / \mathrm { L }$ . Linear regression analysis was also performed and the results are summarized below.

<table><tr><td>SYNCHRON System</td><td>Linear Regression Analysis</td><td>Correlation</td></tr><tr><td>CX5</td><td>y = 0.993x - 0.0498</td><td>R2 = 0.9994</td></tr><tr><td>CX9</td><td>y = 1.0067x - 0.077</td><td>R2 = 0.9993</td></tr><tr><td>LX20</td><td>y = 0.9845x - 0.0385</td><td>R2 = 0.9992</td></tr><tr><td>UniCel DxC 600</td><td>y = 0.994x - 0.0693</td><td>R2 = 0.9994</td></tr><tr><td>UniCel DxC 800</td><td>y = 0.9956x - 0.0447</td><td>R2 = 0.9994</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibrators are not required for this assay. The substrate reagent contains a known concentration of hexacyanoferrate (III), and the assay measures the rate of reduction of this substrate, then determines the molar rate of change using and extinction coefficient of 938.5 at 410/480nm.

Customers will be able to use commercially available controls to verify the performance of the CHEX reagent. Controls are not provided with the CHEX kit. The package insert recommends that at least two levels of controls be analyzed daily and with each new reagent cartridge and specific maintenance and troubleshooting materials as specified in the appropriate analyzer system manual. The insert also states that more frequent use of controls are left to the discretion of the user based on good laboratory practices, laboratory accreditation requirements, and applicable laws.

Onboard reagent stability claims for the SYNCHRON Systems Cholinesterase (CHEX) reagent were validated by recovery experiments using three levels of commercially available controls and a pooled sample. The performance assessment involved assaying control material and pooled sample at regular intervals throughout the testing period. For the SYNCHRON Systems CHEX

Reagent, the onboard stability claim is 30 days and the stability results verified the open cartridge stability claim.

# d. Detection limit:

The limit of the blank (LoB) and limit of detection (LoD) were calculated as recommended in the CLSI guideline EP17-A: “Protocols for Determination of Limits of Detection and Limits of Quantitation: Approved Guideline.” The SYNCHRON Systems Cholinesterase (CHEX) assay has a detection limits claim of $1 . 0 \ : \mathrm { K U / L }$ .

The limits of detection of the SYNCHRON Systems CHEX assay was established by analyzing samples that target the low end analytical range claim on representative members of the SYNCHRON Clinical Chemistry system of analyzers: the UniCel DxC systems, SYNCHRON LX20 PRO system, and SYNCHRON CX PRO systems. 4 samples were used for this study. Each sample was made into 5 dilutions and was run in replicates of 6; this was performed using two lots of reagent, thus providing a total sample population of $\mathrm { N } { = } 2 4 0$ per instrument. An analysis of variance between pools and instruments was determined to be statistically insignificant, so the data was pooled to obtain the average for each instrument. The results of this study are shown below.

<table><tr><td>Instrument</td><td>Sample Range (KU/L)</td><td>Number of Samples</td><td>LOB (KU/L)</td><td>LOD (KU/L)</td><td>LOQ (KU/L)</td></tr><tr><td>CX5</td><td>0.346 - 2.039</td><td>240</td><td>0.448</td><td>0.53</td><td>0.53</td></tr><tr><td>CX9</td><td>0.381 -2.125</td><td>240</td><td>0.486</td><td>0.551</td><td>0.551</td></tr><tr><td>LX20</td><td>0.214-2.019</td><td>240</td><td>0.434</td><td>0.491</td><td>0.623</td></tr><tr><td>DxC 600</td><td>0.283 - 2.076</td><td>240</td><td>0.57</td><td>0.647</td><td>0.647</td></tr><tr><td>DxC 800</td><td>0.252 - 2.065</td><td>240</td><td>0.498</td><td>0.586</td><td>0.61</td></tr><tr><td>Average all Instruments</td><td>0.214 - 2.125</td><td>1200</td><td>0.487</td><td>0.561</td><td>0.561</td></tr></table>

# e. Analytical specificity:

Interference studies were designed from CLSI Guideline EP7-A: “Interference Testing in Clinical Chemistry – Approved Guideline” and used to assess common or known substances which could interfere with the SYNCHRON System Cholinesterase (CHEX) method. Several concentrations of each potential interfering substance were added to patient sample pools at three concentrations of cholinesterase that spanned the claimed measuring range of the device. Each sample was tested in four replicates on representative members of the SYNCHRON family of Clinical Chemistry analyzers: the UniCel DxC systems, SYNCHRON LX20 PRO system, and SYNCHRON CX PRO systems. The difference in recovery between samples with and without the potential interfering substance was calculated to determine if they interfered. The sponsor defined no significant interference (NSI) as a

difference in recovery of less than $10 \%$ . The results are summarized below.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Source</td><td rowspan=1 colspan=1>Level Tested</td><td rowspan=1 colspan=1>Interferences</td></tr><tr><td rowspan=1 colspan=1>Bilirubin(unconjugated)HemoglobinLipemiaAscorbic Acid</td><td rowspan=1 colspan=1>BovineRBC hemolysateIntralipidAscorbic Acid</td><td rowspan=1 colspan=1>60 mg/dL1000 mg/dL2000 mg/dL30 mg/dL</td><td rowspan=1 colspan=1>NSINSINSINSI</td></tr></table>

f. Assay cut-off: Not applicable

2. Comparison studies:

# a. Method comparison with predicate device:

Method comparison studies were designed using CLSI Procedure EP9-A2: “Method Comparison and Bias Estimation Using Patients Samples”. 100 patient serum samples were tested in singlicate on the comparator device and on the UniCel DxC 600, the UniDxC 800, LX20, CX5 Pro, and the CX9 pro and analyzed using Deming regression. Most of the samples tested were natural patient samples with a small number of spiked or diluted samples included to fully cover the measuring range. The results are summarized below.

<table><tr><td>Platform</td><td>Slope</td><td>Intercept</td><td>R</td><td>Samples range tested (kU/L)</td></tr><tr><td>UniCel DxC 600</td><td>0.978</td><td>0.074</td><td>0.999</td><td>1.4 - 14.7</td></tr><tr><td>UniCel DxC 800</td><td>0.969</td><td>0.066</td><td>0.999</td><td>1.4 - 14.7</td></tr><tr><td>LX20</td><td>0.975</td><td>-0.007</td><td>0.999</td><td>1.6- 14.6</td></tr><tr><td>CX5 PRO</td><td>0.993</td><td>-0.064</td><td>0.994</td><td>1.3 - 14.6</td></tr><tr><td>CX9 PRO</td><td>0.98</td><td>0.065</td><td>0.999</td><td>1.4 - 14.7</td></tr></table>

# $b$ . Matrix comparison:

A method comparison study was performed to evaluate the effect of anticoagulants in primary blood collection tubes on cholinesterase recovery on the SYNCHRON System Cholinesterase (CHEX) reagent on the SYNCHRON Clinical Chemistry analyzers. For each anticoagulant, plasma and serum samples from healthy volunteers were drawn and tested, and the plasma recoveries were compared to the corresponding serum recoveries for each donor. Deming regression analysis, with singlicate sample results, was used to evaluate the results. The testing compared 60 sets of paired samples with cholinesterase concentrations ranging from approximately $2 \mathrm { k U / L }$ to 14 kU/L. The results are summarized below.

<table><tr><td>Platform</td><td>Anticoagulant</td><td>Slope</td><td>Intercept</td><td>R</td></tr><tr><td>CX5 PRO CX5 PRO</td><td>Lithium Heparin Sodium Heparin</td><td>0.996 0.992</td><td>-0.048 -0.014</td><td>0.999 0.999</td></tr><tr><td>CX9 PRO CX9 PRO</td><td>Lithium Heparin Sodium Heparin</td><td>1.004 0.998</td><td>-0.102 -0.055</td><td>0.999 0.999</td></tr><tr><td>LX20</td><td>Lithium Heparin</td><td>0.997</td><td>-0.038</td><td>0.999</td></tr><tr><td>LX20 UniCel DxC 600</td><td>Sodium Heparin</td><td>1.004</td><td>-0.071</td><td>0.999</td></tr><tr><td>UniCel DxC 600</td><td>Lithium Heparin Sodium Heparin</td><td>0.992 0.999</td><td>-0.034 -0.095</td><td>0.999 0.999</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>UniCel DxC 800</td><td>Lithium Heparin</td><td>1.009</td><td>-0.154</td><td>0.999</td></tr><tr><td>UniCel DxC 800</td><td>Sodium Heparin</td><td>1.000</td><td>-0.107</td><td>0.999</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: The package insert lists the following reference ranges1 obtained from literature.

<table><tr><td rowspan=1 colspan=1>SAMPLE TYPE</td><td rowspan=1 colspan=1>CONVENTIONAL UNITS</td><td rowspan=1 colspan=1>S.I. UNITS</td></tr><tr><td rowspan=1 colspan=1>Serum or Plasma</td><td rowspan=1 colspan=1>4.9 - 11.9 kU/L or4900 - 11,900 U/L</td><td rowspan=1 colspan=1>81.68 - 198 µkat/L</td></tr></table>

1. Tietz, N. W., Clinical Guide to Laboratory Tests, 3rd Edition, W. B. Saunders, Philadelphia, PA (1995).

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.